NKTR-255 vs placebo to enhance complete responses and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) Meeting Abstract
| Authors: | Ahmed, S.; Dipersio, J. F.; Essell, J. H.; Diefenbach, C. S.; Perales, M. A.; Castilla-Llorente, C.; Dahiya, S.; Chaudhry, S.; Xu, H.; Liu, Y.; Fanton, C.; Lee, Z. C. Y.; Marcondes, M. Q.; Tagliaferri, M.; Zalevsky, J.; Miklos, D. B.; Turtle, C. J.; McGuirk, J. P. |
| Abstract Title: | NKTR-255 vs placebo to enhance complete responses and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 2068 |
| Language: | English |
| ACCESSION: | WOS:001412691900044 |
| DOI: | 10.1182/blood-2024-203576 |
| PROVIDER: | wos |
| Notes: | Source: Wos |
